Ziploc Is Being Sued Over Claims Its Bags Release Harmful Microplastics Into Food
Recently, a class action lawsuit was filed against Wheat Thins, accusing the brand of misrepresenting its ingredients. Now, a popular storage bag brand is under fire after allegedly failing to disclose the risks of its products.
On April 25, 2025, a lawsuit was filed against Ziploc, an S.C. Johnson-owned brand. The lawsuit, filed by Linda Cheslow, alleges that certain Ziploc bags are labeled as 'microwave safe' and suitable for 'freezer' use, giving shoppers the impression they were safe to use in those ways. Cheslow, however, believes the brand is misleading customers and putting them at risk for microplastic consumption. An issue, the plaintiff says, is made worse by Ziploc's claim that its products are reusable.
'These products are made from polyethylene and polypropylene—materials that scientific and medical evidence shows release microplastics when microwaved and frozen—making them fundamentally unfit for microwave and freezer use,' reads page four of the lawsuit document.
Polyethylene and polypropylene are two common food-grade plastic materials used in the production of kitchen goods, including cutting boards, storage containers, and cling wrap, to name a few. When exposed to extreme temperatures, such as heat or cold, they have been found to release microplastics, which can leach into food. Microplastics, while invisible to the naked eye, have been linked to a variety of health concerns, including increased cancer risk, immune dysfunction, and inflammation.
Cheslow believes that the company is putting families at risk by failing to disclose this information, and it's doing so 'for profit and to gain an unfair competitive edge in the marketplace.'
S.C. Johnson has denied these claims, and litigation is ongoing.
This is a class action lawsuit, meaning that it was filed on behalf of all who have purchased the product. At this time, there is no action consumers need to take. In the future, you may be able to file a claim and receive a monetary reward if a settlement fund is established.
The products in question include, but are not limited to:
Ziploc Freezer Bags Pint
Ziploc Freezer Bags Quart
Freezer Bags Gallon
Ziploc Slider Freezer Bags Quart
Ziploc Slider Freezer Gallon
Ziploc Slider Storage Bags Quart
Ziploc Slider Storage Bags Gallon
Ziploc Containers
Additionally, consumers may find photos of the products beginning on page nine of the lawsuit documents. Be sure to take note of which products are included when you compile your receipts and stay up to date as the case proceeds.
Read the original article on ALLRECIPES

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Implantica publishes Interim Report January - June 2025 (Q2)
VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA PMA Submission Completed - Submitted third and final module of the U.S. FDA pre-market approval (PMA) application for RefluxStop®, including responses to questions on the second module; Feedback on module 3 expected in the near-term Produced and completed initial testing on new multi-cavity production tool for RefluxStop® to support launch of manufacturing in U.S. and manage ramp-up of U.S. production (pending FDA approval) Additional preparations for U.S. market launch (pending FDA approval) included U.S. payer and reimbursement activities, finalizing new production facility of RefluxStop® in U.S. and launching our RCT (randomized clinical trial), as a heavyweight cornerstone in building global leadership in acid reflux care Positive NICE Guidance in the UK - UK's National Institute for Health and Care Excellence (NICE) issued positive guidance for the use of RefluxStop® in NHS hospitals for patients with ineffective esophageal motility (IOM/IEM), potentially transforming treatment access for millions and influencing global policy Significant events after the end of the period Landmark 5-Year Clinical Study Results - Two peer-reviewed articles were published in Surgical Endoscopy on our pivotal study results; one publication confirmed outstanding long-term safety and effectiveness outcomes, and the second publication highlighted RefluxStop®'s excellent outcomes in food passageway-related sequelae, which is common in standard of care Randomized Clinical Trial (RCT) Launch - First RCT comparing RefluxStop® with Nissen fundoplication; patient recruitment underway accumulating patients across participating hospitals. While this trial preparation led to a 20% year-on-year revenue decline for Q2, the impact is expected to ease once study recruitment stabilizes Spanish Market Expansion - Three new hospitals added, totaling 19 centers offering RefluxStop® in Spain, with a healthcare sytem receptive for new and better patient care, which is a fantastic launch since 2023 First UK National Users Meeting - Convened 21 top anti-reflux experts to discuss real-world results, operating technique and the opportunities arising from NICE's positive recommendation Financial summary second quarter 2025 Net sales decreased 22% to TEUR 433 (554) due to the launch of the randomized clinical trial with surgeons accumulating patients for the trial. Adjusted gross margin amounted to 90% (91%). Operating loss (EBIT) decreased to TEUR 4,525 (5,869). Loss after tax decreased to TEUR 5,448 (6,431). Basic and diluted loss per Class A share amounted to EUR 0.08 (0.09). Cash and short-term investments as at the end of the period of MEUR 56.3. First six months Net sales increased 2% to TEUR 1,178 (1,150). Adjusted gross margin amounted to 94% (91%). Operating loss (EBIT) decreased to TEUR 8,698 (12,956). Loss after tax decreased to TEUR 8,212 (9,903). Basic and diluted loss per Class A share amounted to EUR 0.12 (0.14). Telephone conference Implantica will hold a teleconference on 14 August 2025 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use the following link: Dial-in Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference. For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company's Certified Adviser is FNCA Sweden AB, info@ This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-14 08:00 CEST. About Implantica: Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop®, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information. This information was brought to you by Cision The following files are available for download: Implantica Q2 2025_ENG Implantica publishes Interim Report Jan - Jun 2025 Q2 View original content:
Yahoo
2 hours ago
- Yahoo
Relief Therapeutics Publishes 2025 Half-Year Report
GENEVAD, SE / / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update. "Relief continued to make steady progress across our pipeline and corporate initiatives," said Dr. Raghuram Selvaraju, chairman of the board of directors. "We advanced RLF‑TD011, our lead wound care candidate, with the receipt of Rare Pediatric Disease designation for epidermolysis bullosa and a productive Type B pre‑IND meeting with the FDA. We also progressed RLF‑OD032, our next‑generation liquid sapropterin formulation for phenylketonuria, toward a pivotal trial expected to begin this quarter. Our focus remains on advancing our core programs, with existing cash reserves projected to fund operations into at least late 2026, beyond the targeted regulatory submission of RLF‑OD032 for approval in the United States. In parallel, we are taking steps to establish a scalable, AI-driven health tech company through the proposed business combination with NeuroX." The report, available on the Company's website , includes interim financial statements for the six months ended June 30, 2025, and a shareholder update. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. In particular, there can be no assurance that the proposed business combination with NeuroX will be completed, as it remains subject to the execution of a definitive agreement, completion of satisfactory due diligence, and other conditions. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
4 hours ago
- Business Insider
Soligenix receives FDA orphan designation for dusquetide
Soligenix's (SNGX) dusquetide, a treatment of Behcet's disease , received FDA orphan designation, according to a post to the agency's website. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>